Source
Yale Medicine
This study is testing an investigational gene-editing treatment designed to reduce the production of transthyretin (TTR), a protein that causes amyloid buildup in the heart. Participants will receive a single intravenous infusion of either the study treatment or placebo and will be followed closely to assess safety and heart-related outcomes.
News Url